Exelixis, Inc.
NASDAQ:EXELBiotechnology
+$0.34 today
- Market cap
- $17.17B
- Beta
- 0.43
- P/E (TTM)
- 16.3
- EPS (TTM)
- $3.23
Volume 1.82M
Average 2.55M
EXEL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Exelixis, Inc.NASDAQ: EXEL
Research & Development · Q2 FY2026 · quarter ended Jul 2026
Research & development growth accelerates
Q2 FY2026 research & development of $211.99M rose 5.8% year over year, ahead of the -6.8% change in trailing-twelve-month research & development. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.
Context
- Research & development amounted to 35.6% of revenue in FY2025, down 6.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +5.8% holds above the trailing-twelve-month pace of -6.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 825M USD
- Year-over-year change
- -9.4%
- 4-year CAGR
- +4.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | 825M | -9.4% |
| FY2024 | 2025-01-03 | 910.41M | -12.8% |
| FY2023 | 2023-12-31 | 1.04B | +17.1% |
| FY2022 | 2022-12-31 | 891.81M | +28.6% |
| FY2021 | 2021-12-31 | 693.72M | — |
Research & Development vs competitors
How EXEL compares with its peers on the latest reported figures
- EXEL's LTM Jul 2026 research & development of $824.32M is the 5th highest of the 8 companies compared; the peer median is $1.29B.
- Its year-over-year change of -6.8% is the 6th highest of 7, against a peer median of +6.4%.
- Research & development amounts to 33.8% of revenue for EXEL, versus a peer median of 34.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $15.01B | -0.3% | +13.4% | 24.1% | |
| LTM Jun 2026 | $2.15B | +9.1% | +8.9% | 37.0% | |
| LTM Jun 2026 | $1.78B | — | -34.5% | 43.1% | |
| LTM Jun 2026 | $1.29B | +68.1% | +57.0% | — | |
| LTM Jul 2026 | $824.32M | -6.8% | -2.6% | 33.8% | |
| LTM Mar 2026 | $255.99M | +3.7% | +29.7% | 117.9% | |
| LTM Jun 2025 | $190.1M | -25.1% | -15.0% | 31.6% | |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| Peer median (excluding EXEL) | $1.29B | +6.4% | +8.9% | 34.3% | |
Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.61B | 1.83B | 2.17B | 2.32B |
| Cost of Revenue | 52.87M | 57.91M | 72.55M | 76.22M | 83.7M |
| Gross Profit | 1.38B | 1.55B | 1.76B | 2.09B | 2.24B |
| Gross Margin | 96.3% | 96.4% | 96.0% | 96.5% | 96.4% |
| Research & Development | 693.72M | 891.81M | 1.04B | 910.41M | 825M |
| Selling, General & Admin | 401.72M | 459.86M | 542.71M | 492.13M | 518.73M |
| Operating Expenses | 1.1B | 1.35B | 1.59B | 1.49B | 1.36B |
| Depreciation & Amortization | 13.63M | 20.88M | 25.72M | 28.8M | 29.06M |
| EBITDA | 307.78M | 255.23M | 283.24M | 718.75M | 921.76M |
| EBITDA Margin | 21.4% | 15.8% | 15.5% | 33.1% | 39.7% |
| Operating Income | 286.67M | 201.48M | 170.89M | 604.62M | 872.19M |
| Operating Margin | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| Interest Income | 7.67M | 33.07M | 86.54M | 77.16M | 69.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7.49M | 32.87M | 86.64M | 77.02M | 69.02M |
| Income Before Tax | 294.15M | 234.35M | 257.52M | 681.64M | 941.21M |
| Pre-Tax Margin | 20.5% | 14.5% | 14.1% | 31.4% | 40.6% |
| Income Tax Expense | 63.09M | 52.07M | 49.76M | 160.37M | 158.64M |
| Net Income | 231.06M | 182.28M | 207.77M | 521.27M | 782.57M |
| Net Margin | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| EPS (Basic) | 0.73 | 0.57 | 0.65 | 1.80 | 2.88 |
| EPS (Diluted) | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 |
| Weighted Avg Shares | 314.88M | 321.53M | 318.15M | 290.03M | 271.57M |
| Weighted Avg Shares (Diluted) | 322.36M | 324.56M | 321.46M | 296.13M | 281.86M |
Exelixis, Inc.
NASDAQ:EXEL
Intrinsic Alpha fair value
Locked
Current Price
$68.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.